Back to Newsroom

Aethlon Announces Initiation of Sepsis-Related Virus Study

SAN DIEGO, Dec. 15, 2016 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has initiated a research study to validate the ability of the Aethlon Hemopurifier® to capture viruses that are associated with increased mortality in immune-suppressed sepsis patients. The study is designed to validate the in vitro capture of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex Viruses (HSV).  Upon successful completion, Aethlon will seek to demonstrate that the Hemopurifier can simultaneously capture all three viruses.

Click here to read the full release